The following key points are highlighted in connection with the report:

• Weak sales quarter – recovery expected in Q4-25
• Continued strong gross margin
• Sales development and one-off costs affected the result – profitability still expected in Q4-25
• Ongoing in-depth discussions with pharmaceutical companies regarding Drug Delivery

In summary, Nosa Plugs’ Q3 report reflected a temporarily weaker quarter in terms of sales, with recovery expected already in Q4-25. Sales were affected by order shifts and reduced sales activities, while the gross margin reached a record 74.3%, confirming the impact of prior production efficiencies. The acquisition of Pharmacure strengthens the product portfolio and is expected to contribute positively to both revenue and margins going forward. Analyst Group expects sales to rebound in Q4-25, supported by resumed sales efforts and a full-quarter contribution from the Nozoil acquisition, resulting in a positive EBITDA outcome. Additionally, we continue to see significant value potential in the Drug Delivery project, where a potential partnership with a pharmaceutical company could serve as a major value catalyst for Nosa Plugs.

Read Analyst Group’s comment on the report here

About Analyst Group: One of Sweden's leading equity research boutiques with focus on small and medium-sized listed companies.
Read more about Analyst Group
 
This is a press release from Analyst Group regarding the publication of a comment on Nosa Plugs. Readers may assume that Analyst Group has received compensation for making the comment. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.